Scarica l'app Stockscreener
5.53
3.17%
0.17
Dopo l'orario di chiusura:
5.58
0.05
+0.90%
Precedente Chiudi:
$5.36
Aprire:
$5.4088
Volume 24 ore:
295.04K
Relative Volume:
0.26
Capitalizzazione di mercato:
$331.22M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-7.3733
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
+7.17%
1M Prestazione:
+79.25%
6M Prestazione:
+9.94%
1 anno Prestazione:
+37.91%
Intervallo 1D:
$5.385
$5.55
Intervallo di 1 settimana:
$4.88
$5.6552
Portata 52W:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Confronta ALDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.53 | 321.04M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
What analysts say about Aldeyra Therapeutics Inc. stockUnprecedented growth rates - Autocar Professional
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
What drives Aldeyra Therapeutics Inc. stock priceHigh-impact stock picks - jammulinksnews.com
Is Aldeyra Therapeutics Inc. a good long term investmentHigh-octane financial growth - Autocar Professional
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare
FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus
Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard
FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks
FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com
FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan
How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
(ALDX) Trading Report - news.stocktradersdaily.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus
Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com
Aldeyra receives FDA special protocol assessment for lymphoma drug By Investing.com - Investing.com Canada
Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus
When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com
Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive
Aldeyra resubmits NDA for dry eye disease drug after trial success - Investing.com
Aldeyra resubmits NDA for dry eye disease drug after trial success By Investing.com - Investing.com South Africa
Aldeyra Therapeutics (ALDX) Resubmits FDA Application for Dry Ey - GuruFocus
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):